Elara MD review

Elara MD prices sermorelin injections from $349 a month and NAD⁺ and glutathione injections from $249 a month. The $249 sermorelin mini-troche selector does not establish a billing period. Its FAQ names Strive Pharmacy and Beluga Health, a useful starting point for sourcing questions, though the assigned dispenser, legal operator and individual medical director remain unclear. Monthly renewal requires clinician review and patient payment, with no automatic monthly debit. Cancellation deadlines conflict across its public policies.

Elara MD describes itself as an online compounding retailer founded by physicians practicing wellness medicine. It offers sermorelin injections and sublingual mini-troches, glutathione and NAD⁺ injections, alongside injectable plans marketed as Personalized GLP-1 + B12 and GLP-1/GIP + B12, with microdosing options. Its FAQ names Strive Pharmacy in Gilbert, Arizona, and Beluga Health as its provider network. A registered legal operator and individual medical director are not identified. It displays a LegitScript seal. This review covers Elara MD.

An online questionnaire leads to clinician review and a treatment plan if prescribed. The FAQ says payment is taken when medication ships according to the selected plan; monthly renewal involves notification and another clinician review, and the patient must process payment rather than being automatically debited. Product pages advertise free shipping in one to four days, which does not guarantee total time from intake to delivery. Strive Pharmacy and Beluga Health are named, but confirm the assigned pharmacy and treating clinician for your product; terms allow requesting a different pharmacy before ordering. The homepage claims over 40 states while the FAQ says nationwide, without a state list. NAD⁺ and sermorelin injections exclude California. Footer exclusions for NAD⁺ troches in Arkansas, Indiana, Kentucky, Michigan, Minnesota and South Carolina neither establish an orderable troche nor apply to the injections. The FAQ says 18+ and no insurance; terms limit service to the US and its territories, and guardian language does not establish pediatric treatment. Terms use Georgia governing law but San Diego arbitration under California law. Privacy disclosures include pharmacy comparison, discount-coupon and partner-marketing functions.

Sermorelin injections start at $349 a month; NAD⁺ and glutathione injections each start at $249 a month. The sublingual sermorelin mini-troche selector shows $249 at the starting option without an explicit billing period. GLP-1 + B12 starts at $199 a month and GLP-1/GIP + B12 at $249 a month; a maintenance-dose table is not provided. These figures do not establish prescribed strength, quantity, supply, complete first charge or consultation contingencies. Billing occurs at shipment under the chosen plan, with manual payment for monthly renewals. Cancellation rules differ: the FAQ says orders cannot be changed or canceled after submission, while the refund policy permits changes or cancellation before shipping. Prescription sales are final after charge and carrier handoff, with no return after dispensing. Lost shipments may be traced and reshipped; damage requires support review. Get the deadline for your order in writing.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Elara MD calls itself a compounding retailer, and its GLP-1/GIP page describes Section 503A preparation rather than a substitute for FDA-approved products. It does not name the molecules behind its GLP-1 labels. The FAQ names Strive Pharmacy, and terms permit patient-directed pharmacy choice; the assigned dispenser needs confirmation. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, the wellness line splits three ways. Sermorelin, as an injection or a troche, acts on the growth-hormone axis, a real mechanism with thin long-term human outcome data; the troche route has no published comparative absorption data. Injectable glutathione has essentially no controlled human outcome evidence. Injected NAD⁺ has no controlled outcome trials either; the oral precursors NR and NMN raise blood NAD⁺, a biomarker rather than a clinical outcome. Individual results vary.